Post-Exposure Prophylaxis for Measles

Immediate Management and Isolation

• The child with active measles symptoms should be immediately isolated and kept out of school or daycare for at least 4 days after rash onset, as patients are contagious from 4 days before rash to 4 days after rash appears, according to the American Academy of Pediatrics 1

Post-Exposure Prophylaxis for Contacts

• MMR vaccine is the preferred post-exposure prophylaxis and should be administered within 72 hours of initial measles exposure to susceptible household contacts aged ≥6 months who can receive the vaccine, as recommended by the Centers for Disease Control and Prevention 2
• Susceptible contacts include anyone without documentation of two doses of measles-containing vaccine after their first birthday or other acceptable evidence of immunity, according to the Centers for Disease Control and Prevention 3
• Vaccinated persons may be readmitted to school immediately, while unvaccinated persons must be excluded for 21 days after rash onset in the last case, as recommended by the Centers for Disease Control and Prevention 3

Immune Globulin for High-Risk Contacts

• For contacts who cannot receive MMR vaccine or were not vaccinated within 72 hours, immune globulin should be administered within 6 days of exposure, with a standard dose of 0.25 mL/kg IM (maximum 15 mL) for immunocompetent persons, as recommended by the Centers for Disease Control and Prevention 2
• High-risk groups requiring IG include infants <12 months, pregnant women, and immunocompromised persons, according to the Centers for Disease Control and Prevention 2

School and Community Control Measures

• All susceptible students, siblings, and school personnel in affected schools should receive MMR vaccination immediately during an outbreak, as recommended by the Centers for Disease Control and Prevention 3
• Persons without documentation of adequate vaccination (two doses separated by ≥28 days after first birthday) should be vaccinated or excluded from school for 21 days after the last case's rash onset, according to the Centers for Disease Control and Prevention 3
• Revaccination should extend to unaffected schools in the same geographic area that may be at risk for measles transmission, as recommended by the Centers for Disease Control and Prevention 3

Vaccine Formulation and Administration

• Monovalent measles vaccine is only preferred for infants aged 6-11 months during outbreaks, but MMR may be used if monovalent vaccine is not readily available, according to the Centers for Disease Control and Prevention 3, 4
• For children ≥12 months, MMR vaccine is the standard and preferred formulation, as recommended by the American Academy of Pediatrics 1

Measles and Rubella Prevention and Treatment

Primary Prevention: Vaccination Strategy

• The Centers for Disease Control and Prevention recommends a two-dose MMR vaccine schedule, administered at 12-15 months for the first dose and 4-6 years for the second dose, achieving >99% reduction in both diseases since vaccine licensure 5, 6
• The American Academy of Pediatrics suggests that the first dose of MMR vaccine can be given as early as 12 months in high-risk areas 7, 6
• The two-dose schedule addresses primary vaccine failure, which occurs in approximately 5% of recipients after a single dose 7, 8
• Almost all persons who fail to respond to the first dose will develop immunity after the second dose 7, 9

Disease Severity and Clinical Implications

• Measles is significantly more severe than rubella, with mortality occurring in 1-2 per 1,000 cases and encephalitis in 1 per 1,000 cases, making aggressive prevention critical 10, 11
• The World Health Organization reports that the incubation period for measles is 10-12 days to prodrome, 14 days to rash (range: 7-18 days) 10, 11
• Common complications of measles include diarrhea, otitis media, and bronchopneumonia 10, 11
• Serious complications of measles include encephalitis (often causing permanent brain damage) and death 10, 11

Post-Exposure Prophylaxis

• The Centers for Disease Control and Prevention recommends that MMR vaccine be administered within 72 hours of measles exposure to prevent or modify disease 12, 13
• For susceptible contacts not vaccinated within 72 hours, immunocompetent persons should receive 0.25 mL/kg IM (maximum 15 mL) of immune globulin, while immunocompromised persons should receive 0.5 mL/kg IM (maximum 15 mL) 12

Outbreak Control Strategies

• The World Health Organization suggests that any single confirmed measles case constitutes an urgent public health situation requiring immediate vaccination of all susceptible persons at risk for exposure 8
• Prompt vaccination of susceptible persons may prevent dissemination, and all persons without acceptable evidence of immunity should be vaccinated or excluded from outbreak settings (schools, day care, hospitals) 8

Special Populations

• The Centers for Disease Control and Prevention recommends that MMR vaccine is contraindicated during pregnancy 5, 6
• Measles during pregnancy increases rates of premature labor, spontaneous abortion, and low birth weight 11
• Severely immunocompromised HIV patients should receive immune globulin prophylaxis if exposed to measles, regardless of vaccination status 12

Post-Exposure Prophylaxis for Infants After Measles Exposure

Rationale for Immunoglobulin Administration

• Infants under 6 months, such as the 5-month-old infant in this scenario, are typically protected by maternally derived antibodies, but this protection is not guaranteed, and they may require additional protection unless exposed to measles, according to the Centers for Disease Control and Prevention (CDC) 14, 15, 16
• The American Academy of Pediatrics recommends that infants aged less than 6 months who are household contacts of measles patients should receive immune globulin as post-exposure prophylaxis, with a standard dose of 0.25 mL/kg IM (maximum 15 mL) for immunocompetent persons, which must be administered within 6 days of exposure to be effective 14, 15, 16

Vaccination Guidelines

• The CDC recommends that MMR vaccine is only considered for infants aged 6-11 months in outbreak or high-risk exposure situations, not for 5-month-olds, and that MMR vaccination is most effective within 72 hours of initial exposure 17, 15, 18
• The CDC also states that any MMR dose given before 12 months must be followed by two additional doses: the first at 12-15 months and the second at least 28 days later, as IG provides only temporary passive immunity 19, 17, 15

Measles Treatment and Management

Introduction to Measles Treatment

• The Centers for Disease Control and Prevention recommends that measles treatment is primarily supportive care, as there is no specific antiviral therapy for the disease; however, vitamin A supplementation is critical for reducing morbidity and mortality, particularly in children, and immunocompromised patients require immune globulin (IG) for post-exposure prophylaxis regardless of vaccination status 20, 21

Special Populations Requiring Enhanced Management

• Immunocompromised patients face severe, prolonged measles illness and require aggressive prophylaxis and monitoring, with post-exposure prophylaxis with IG being mandatory for exposed symptomatic HIV-infected and other immunocompromised persons, regardless of previous vaccination status 20, 21, 22
• The American Academy of Pediatrics recommends that the recommended IG dose for immunocompromised patients is 0.5 mL/kg IM (maximum 15 mL), which is double the standard dose, as usual doses may not be effective 21, 22
• Measles may present without the typical rash in immunocompromised individuals, and patients may shed virus for several weeks after acute illness 20

Vaccination and Post-Exposure Prophylaxis

• The Centers for Disease Control and Prevention recommends that MMR vaccine is contraindicated during active chemotherapy or immunosuppressive therapy with corticosteroids (≥2 mg/kg/day prednisone equivalent for ≥14 days), alkylating drugs, antimetabolites, or radiation 21, 22
• Patients with leukemia in remission may receive MMR vaccine only after at least 3 months have elapsed since termination of chemotherapy 21, 22, 23

Complications Requiring Specific Management

• The World Health Organization notes that measles complications occur in 10-40% of patients and include pneumonia (most common cause of death), encephalitis (1 per 1,000 cases), and diarrhea and otitis media, which require aggressive respiratory support, intensive supportive care, and symptomatic treatment and antibiotics for bacterial superinfection 20

MMR Vaccination Guidelines

Introduction to MMR Vaccination

• The Centers for Disease Control and Prevention recommends that MMR vaccine can be administered as early as 6 months of age during measles outbreaks or high-risk exposure situations, though monovalent measles vaccine is preferred if available; however, any dose given before 12 months does not count toward the routine series and must be followed by two additional doses starting at 12-15 months 24

Routine Vaccination Schedule

• The American Academy of Pediatrics recommends that the standard minimum age for MMR vaccination is 12 months, with the first dose routinely administered at 12-15 months and the second dose at 4-6 years 25

Early Vaccination in Special Circumstances

• During measles outbreaks, vaccination of infants as young as 6 months may be undertaken as an outbreak control measure, particularly when cases are occurring among infants under 12 months 24
• Monovalent measles vaccine is the preferred formulation for infants 6-11 months during outbreaks, but MMR may be used if monovalent vaccine is not readily available 24

Critical Revaccination Requirements

• Children vaccinated with measles or MMR vaccine before their first birthday must be revaccinated at age 12-15 months and again before entering school (typically 4-6 years) 24

Common Pitfalls to Avoid

• The Centers for Disease Control and Prevention advises that any MMR dose given before 12 months should not be counted toward the routine two-dose series 24
• For infants under 6 months who are household contacts of measles patients, immune globulin (IG) at 0.25 mL/kg IM (maximum 15 mL) is preferred over vaccination, administered within 6 days of exposure 24

Monovalent Measles Vaccine vs MMR at 9 Months

Guideline Recommendations for 9-Month-Olds

• The Centers for Disease Control and Prevention (CDC) guideline notes that MMR should generally be used whenever any of its component vaccines is indicated, and monovalent vaccines are reserved only when the recipient has acceptable evidence of immunity to one or two MMR components, as stated in the 1998 guidelines 26
• Using MMR at 9 months eliminates the need to track which antigens the child has received and simplifies the vaccination schedule, according to the 1998 guidelines 26

Practical Considerations

• Any dose given before 12 months (whether monovalent or MMR) must be followed by two additional MMR doses: the first at 12-15 months and the second at least 28 days later, as recommended by the guidelines 26